• Oryzon Genomics shareholders will vote at an extraordinary meeting on a five-year authorization to issue up to EUR 100 million.
• The proposal covers fixed-income securities, preferred shares and similar instruments, including securities convertible into or exchangeable for company shares.
• Capital increases to cover conversions or warrant exercises, combined with other delegated increases, would be capped at 50% of share capital.
• The board also seeks authority to exclude preemptive subscription rights for convertible securities or warrants representing up to 20% of share capital.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oryzon Genomics SA published the original content used to generate this news brief on November 13, 2026, and is solely responsible for the information contained therein.